{"id":23030,"date":"2023-10-31T01:35:00","date_gmt":"2023-10-31T01:35:00","guid":{"rendered":"https:\/\/www.prnasia.com\/story\/archive\/4253373_AE53373_0"},"modified":"2023-10-31T01:35:00","modified_gmt":"2023-10-31T01:35:00","slug":"affamed-therapeutics-announced-positive-top-line-results-from-real-world-study-in-china-evaluating-the-safety-and-efficacy-of-dextenza-in-patients-after-cataract-surgery","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=23030","title":{"rendered":"AffaMed Therapeutics Announced Positive Top-Line Results from Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA\u00ae in Patients after Cataract Surgery"},"content":{"rendered":"\n<p><span class=\"xn-location\">SHANGHAI<\/span>, <span class=\"xn-chron\">Oct. 31, 2023<\/span> \/PRNewswire\/ &#8212; AffaMed Therapeutics (&quot;AffaMed&quot;), a global biotechnology company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products&nbsp;that address critical unmet medical needs in ophthalmological, neurological and psychiatric disorders, announced positive top-line results from the Real-World Study conducted in the Boao Lecheng Pilot Zone in <span class=\"xn-location\">Hainan, China<\/span>, to evaluate the safety and efficacy of DEXTENZA&reg; (0.4 mg dexamethasone ophthalmic insert) for the treatment of ocular inflammation and pain following cataract surgery.<\/p>\n<ul type=\"disc\">\n<li>The trial met its primary endpoint, with&nbsp;Dextenza demonstrating a significant reduction of ocular inflammation as measured by the absence of anterior chamber cells (i.e. score of &quot;0&quot;) in the study eye on Day 14 after cataract surgery.<\/li>\n<li>The trial also met its secondary endpoint, demonstrating a significant reduction of ocular pain on Day 8.<\/li>\n<li>Dextenza was well-tolerated and had a favorable safety profile consistent with all prior trials.<\/li>\n<\/ul>\n<p>&quot;We are thrilled to announce the positive topline results from our Real-World Study in cataract surgery patients,&quot; Dr. <span class=\"xn-person\">Dayao Zhao<\/span>, CEO of AffaMed commented, &quot;Dextenza shows great efficacy and safety in Chinese patients, and this is a significant milestone for AffaMed in advancing this late-stage program towards registration in Mainland China&quot;.<\/p>\n<p>In <span class=\"xn-chron\">October 2020<\/span>, AffaMed Therapeutics entered into a licensing agreement with Ocular Therapeutix, Inc. (NASDAQ: OCUL) for the development and commercialization of DEXTENZA in <span class=\"xn-location\">Greater China<\/span>, <span class=\"xn-location\">South Korea<\/span>, and certain ASEAN markets. DEXTENZA is approved in the U.S. and Macau SAR for the treatment of ocular inflammation and pain following ophthalmic surgery, and ocular itching associated with allergic conjunctivitis.<\/p>\n<p>AffaMed is developing DEXTENZA to become the first sustained-release intracanalicular insert in <span class=\"xn-location\">China<\/span> delivering a preservative-free dose of dexamethasone for up to 30 days with a single administration. This product offers patients significant benefits and convenience vs. current standard of care requiring multiple daily administrations of&nbsp;eyedrops.<\/p>\n<p><b>About AffaMed Therapeutics<\/b><\/p>\n<p>AffaMed Therapeutics is a clinical stage biopharmaceutical company focused on developing and commercializing transformative pharmaceutical, digital and surgical products that address critical unmet medical needs in ophthalmological, neurological and psychiatric disorders for patients in <span class=\"xn-location\">Greater China<\/span> and around the world. The leadership team at AffaMed Therapeutics has gained deep industry expertise and an extensive track record in high-quality discovery, clinical development, regulatory affairs, business development, manufacturing, and commercial operations at leading multi-national biopharmaceutical companies in <span class=\"xn-location\">China<\/span> and globally.<\/p>\n<p><b>About DEXTENZA<\/b><\/p>\n<p>DEXTENZA is FDA-approved for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis. DEXTENZA is a corticosteroid intracanalicular insert placed in the punctum, a natural opening in the inner portion of the lower eyelid, and into the canaliculus and is designed to deliver dexamethasone to the ocular surface for up to 30 days without preservatives. DEXTENZA resorbs and exits the nasolacrimal system without the need for removal.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>SHANGHAI, Oct. 31, 2023 \/PRNewswire\/ &#8212; AffaMed Therapeutics (&quot;AffaMed&quot;), a global biotechnology company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products&nbsp;that address critical unmet medical needs in ophthalmological, neurological and psychiatric disorders, announced positive top-line results from the Real-World Study conducted in the Boao Lecheng Pilot Zone in Hainan, China, to evaluate [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-23030","post","type-post","status-publish","format-standard","hentry","category-business-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AffaMed Therapeutics Announced Positive Top-Line Results from Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA\u00ae in Patients after Cataract Surgery - My Blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/transmediavictoria.net.au\/?p=23030\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AffaMed Therapeutics Announced Positive Top-Line Results from Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA\u00ae in Patients after Cataract Surgery - My Blog\" \/>\n<meta property=\"og:description\" content=\"SHANGHAI, Oct. 31, 2023 \/PRNewswire\/ &#8212; AffaMed Therapeutics (&quot;AffaMed&quot;), a global biotechnology company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products&nbsp;that address critical unmet medical needs in ophthalmological, neurological and psychiatric disorders, announced positive top-line results from the Real-World Study conducted in the Boao Lecheng Pilot Zone in Hainan, China, to evaluate [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/transmediavictoria.net.au\/?p=23030\" \/>\n<meta property=\"og:site_name\" content=\"My Blog\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-31T01:35:00+00:00\" \/>\n<meta name=\"author\" content=\"admin_tony\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin_tony\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=23030#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=23030\"},\"author\":{\"name\":\"admin_tony\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"headline\":\"AffaMed Therapeutics Announced Positive Top-Line Results from Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA\u00ae in Patients after Cataract Surgery\",\"datePublished\":\"2023-10-31T01:35:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=23030\"},\"wordCount\":490,\"articleSection\":[\"Business News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=23030\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=23030\",\"name\":\"AffaMed Therapeutics Announced Positive Top-Line Results from Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA\u00ae in Patients after Cataract Surgery - My Blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\"},\"datePublished\":\"2023-10-31T01:35:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=23030#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=23030\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=23030#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AffaMed Therapeutics Announced Positive Top-Line Results from Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA\u00ae in Patients after Cataract Surgery\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\",\"name\":\"My Blog\",\"description\":\"My WordPress Blog\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\",\"name\":\"admin_tony\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"caption\":\"admin_tony\"},\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?author=8\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AffaMed Therapeutics Announced Positive Top-Line Results from Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA\u00ae in Patients after Cataract Surgery - My Blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/transmediavictoria.net.au\/?p=23030","og_locale":"en_US","og_type":"article","og_title":"AffaMed Therapeutics Announced Positive Top-Line Results from Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA\u00ae in Patients after Cataract Surgery - My Blog","og_description":"SHANGHAI, Oct. 31, 2023 \/PRNewswire\/ &#8212; AffaMed Therapeutics (&quot;AffaMed&quot;), a global biotechnology company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products&nbsp;that address critical unmet medical needs in ophthalmological, neurological and psychiatric disorders, announced positive top-line results from the Real-World Study conducted in the Boao Lecheng Pilot Zone in Hainan, China, to evaluate [&hellip;]","og_url":"https:\/\/transmediavictoria.net.au\/?p=23030","og_site_name":"My Blog","article_published_time":"2023-10-31T01:35:00+00:00","author":"admin_tony","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin_tony","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/transmediavictoria.net.au\/?p=23030#article","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/?p=23030"},"author":{"name":"admin_tony","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"headline":"AffaMed Therapeutics Announced Positive Top-Line Results from Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA\u00ae in Patients after Cataract Surgery","datePublished":"2023-10-31T01:35:00+00:00","mainEntityOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=23030"},"wordCount":490,"articleSection":["Business News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/transmediavictoria.net.au\/?p=23030","url":"https:\/\/transmediavictoria.net.au\/?p=23030","name":"AffaMed Therapeutics Announced Positive Top-Line Results from Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA\u00ae in Patients after Cataract Surgery - My Blog","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/#website"},"datePublished":"2023-10-31T01:35:00+00:00","author":{"@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"breadcrumb":{"@id":"https:\/\/transmediavictoria.net.au\/?p=23030#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/transmediavictoria.net.au\/?p=23030"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/transmediavictoria.net.au\/?p=23030#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/transmediavictoria.net.au\/"},{"@type":"ListItem","position":2,"name":"AffaMed Therapeutics Announced Positive Top-Line Results from Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA\u00ae in Patients after Cataract Surgery"}]},{"@type":"WebSite","@id":"https:\/\/transmediavictoria.net.au\/#website","url":"https:\/\/transmediavictoria.net.au\/","name":"My Blog","description":"My WordPress Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/transmediavictoria.net.au\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7","name":"admin_tony","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","caption":"admin_tony"},"url":"https:\/\/transmediavictoria.net.au\/?author=8"}]}},"_links":{"self":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/23030","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=23030"}],"version-history":[{"count":0,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/23030\/revisions"}],"wp:attachment":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=23030"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=23030"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=23030"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}